FDA Calendar Tweet Share PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks. Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Amarin Corp Plc AMRN Vascepa (sNDA) FDA decision on expansion of Vascepa labeling based on the REDUCE-IT cardiovascular outcomes study. 12/28/2019 -Drug Status